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We hypothesize that the mushroom-derived active compound may be a potential strategy for increasing survival in response to
inﬂuenza virus (H1N1) infection through the stimulation of host innate immune response. The validity of the hypothesis can be
tested by immune response to inﬂuenza infection as seen through survival percentage, virus clearance, weight loss, natural killer
cell cytotoxicity, Tumor Necrosis Factor-α (TNF-α) and Interferon-gamma (IFN-γ)l e v e l s ,l y t i ce ﬃciency in the spleens of mice
and inducible nitric oxide synthase mRNA expressions in RAW 264.7 murine macrophage cells. The hypothesis may improve
people’s quality of life, reduce the medical cost of our healthcare system and eliminate people’s fears of inﬂuenza outbreak.
1.Introduction
The Pandemic (H1N1) 2009 has aﬀected many countries
and has already caused many human deaths. Fears are that
further mutations in the virus could lead to a potentially
more dangerous outbreak. Although vaccines are eﬀective
in preventing infection, vaccine coverage is incomplete and
improvement in immunization is needed. The antiviral
drugs such as amantadine and rimantadine now available
for prophylaxis and treatment of inﬂuenza are limited by the
rapid emergence of resistant virus mutants in the clinic.
As immune systems rely heavily on innate defenses, it
has been suggested that stimulation of host innate immune
response might provide prophylactic protection against
inﬂuenza infection [1].
Considerable information and research exist on the iden-
tiﬁcation of the biologically active components of medicinal
mushrooms and on their use as therapies and immune sys-
tem modulators. Mushrooms are of great interest due to the
large number of biologically active compounds they contain.
Some complexes from mushrooms are able to stimulate
the non-speciﬁc immune system through the stimulation of
the host’s defence mechanism [2–16]. The immunomodu-
latory actions associated with mushrooms intake have been
suggested as being due to a number of isolated fractions
from mushrooms, including the β-d-glucans and other
polysaccharides [17–19].
2. The Hypothesis
Mushrooms need antiviral compounds to survive in their
natural environment. It is therefore not surprising that
antiviral compounds with more or less strong activities
can be isolated from many mushrooms. Numerous studies
have indicated that the antiviral eﬀects of mushrooms result
from the immunostimulating activity of polysaccharides or
other complex molecules [17–22]. Active hexose correlated
compound is a natural mushroom extract that has been
reported to boost natural killer (NK) activity, improve
survival and reduce the severity of H5N1 avian inﬂuenza
in young mice [20]. The white button extracts readily
stimulate macrophage production of TNF-α [21]. Ganoder-
madiol, lucidadiol and applanoxidic acid G isolated from the
European Basidiomycete Ganoderma pfeiﬀeri show antiviral
activity against inﬂuenza virus type A and Herpes Simplex
Virus type1 [22]. Taking all these together, we hypothesize2 Evidence-Based Complementary and Alternative Medicine
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Figure 1: Diagram illustrating processing scheme of supplementa-
tion with MDAC to modulate immunity and increase survival in
response to inﬂuenza virus (H1N1) infection.
that the mushroom-derived active compound (MDAC) will
modulate immunity and increase survival in response to
inﬂuenza virus (H1N1) infection (Figure 1).
3.Testing the Hypothesis
3.1. Isolated MDAC from Mushrooms. Ganoderma lucidum,
Coprinus comatus, Grifola frondosa and other species fungi
of basidiomycetes are collected in China. Triterpenes, phe-
nolic compounds, oligosaccharides, polysaccharides and
polysaccharide-protein complexes are isolated, respectively.
T h e s em u s h r o o m - d e r i v e da c t i v ec o m p o u n d( M D A C )a r e
evaluated the eﬀects of them on the immune response to
inﬂuenza infection.
3.2.InﬂuenzaVirusInfection. Miceareanesthetizedbyintra-
peritoneal injection with Avertin and infected intranasally
with the speciﬁed dose of H1N1 strain of mouse-adapted
inﬂuenza A virus. The mice are monitored and weighed
daily. This study should be performed in accordancewiththe
Guidelines for Ethical Conduct in the Care and Use of Ani-
mals developed by the American Psychological Association.
Care was taken to minimize discomfort, distress and pain to
the animals.
3.3. Evaluation of Eﬀects of MDAC on the Immune Response to
InﬂuenzaInfection. ThemicearesupplementedwithMDAC.
Survival percentage, virus clearance, weight loss, NK cell
cytotoxicity, TNF-α and IFN-γ levels, lytic eﬃciency in the
spleens of mice and inducible nitric oxide synthase mRNA
expressions in RAW 264.7 murine macrophage cells are
analyzed.
4. Conclusions andFutureStudies
In this article, we suggest that the MDAC may be a potential
strategy to increase survival in response to inﬂuenza virus
(H1N1) infection through the stimulation of host innate
immune response. This hypothesis represents a completely
novel area of study, which will lead to valuable treatments
for and/or preventions of inﬂuenza virus (H1N1) infection.
If the hypothesis is supported by further experimentation,
it may improve people’s quality of life, reduce the medical
cost of our healthcare system and eliminate people’s fears of
inﬂuenza outbreak.
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